Loading...
XBRUFAGR
Market cap1.38bUSD
Dec 20, Last price  
18.12EUR
1D
-0.66%
1Q
-3.00%
Jan 2017
86.55%
IPO
94.99%
Name

Fagron NV

Chart & Performance

D1W1MN
XBRU:FAGR chart
P/E
18.75
P/S
1.73
EPS
0.97
Div Yield, %
1.38%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
10.10%
Revenues
763m
+11.57%
283,284,000283,248,000276,971,000304,368,000354,506,000391,315,000424,056,000492,330,000547,020,000386,119,000447,056,000472,996,000421,839,000436,934,000471,679,000534,695,000555,971,000573,808,000683,881,000762,991,000
Net income
71m
+1.34%
13,798,00015,063,00012,123,00016,260,00014,900,00019,639,00022,479,00028,140,00043,906,000-32,102,00016,226,000-202,328,000-20,562,00046,658,00042,486,00055,687,00059,601,00061,004,00069,612,00070,547,000
CFO
107m
-1.90%
9,038,00034,541,00017,570,00027,100,00027,741,00039,496,00042,126,00072,147,00067,744,00063,078,000101,696,00073,311,00067,504,00084,247,00073,278,00077,175,00092,953,00078,419,000109,458,000107,379,000
Dividend
May 21, 20240.3 EUR/sh
Earnings
Feb 13, 2025

Profile

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
URL
https://fagron.com/
IPO date
Oct 05, 2007
Employees
3,035
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
762,991
11.57%
683,881
19.18%
573,808
3.21%
Cost of revenue
609,644
400,018
328,479
Unusual Expense (Income)
NOPBT
153,347
283,863
245,329
NOPBT Margin
20.10%
41.51%
42.75%
Operating Taxes
13,401
17,703
15,442
Tax Rate
8.74%
6.24%
6.29%
NOPAT
139,946
266,160
229,887
Net income
70,547
1.34%
69,612
14.11%
61,004
2.35%
Dividends
(18,265)
(14,571)
(13,028)
Dividend yield
1.51%
1.51%
1.21%
Proceeds from repurchase of equity
1,036
453
49,284
BB yield
-0.09%
-0.05%
-4.58%
Debt
Debt current
9,678
19,009
14,318
Long-term debt
398,769
423,615
359,476
Deferred revenue
1
6,112
Other long-term liabilities
5,029
6,647
1,000
Net debt
264,146
296,069
298,683
Cash flow
Cash from operating activities
107,379
109,458
78,419
CAPEX
(38,473)
(18,497)
(20,731)
Cash from investing activities
(44,757)
(69,269)
(31,923)
Cash from financing activities
(57,025)
13,852
(61,648)
FCF
156,720
219,223
196,034
Balance
Cash
137,276
125,337
70,647
Long term investments
7,025
21,218
4,464
Excess cash
106,151
112,361
46,421
Stockholders' equity
734,676
677,532
621,443
Invested Capital
733,247
663,527
605,483
ROIC
20.04%
41.95%
40.45%
ROCE
18.23%
36.38%
37.49%
EV
Common stock shares outstanding
73,000
72,886
72,715
Price
16.61
25.17%
13.27
-10.34%
14.80
-22.11%
Market cap
1,212,530
25.37%
967,197
-10.13%
1,076,182
-21.75%
EV
1,480,548
1,517,434
1,657,380
EBITDA
187,869
315,160
271,812
EV/EBITDA
7.88
4.81
6.10
Interest
22,979
10,620
8,006
Interest/NOPBT
14.98%
3.74%
3.26%